CAR T-cell therapy as a part of adoptive cell therapy (ACT), has become one of the most rapidly growing and promising fields in the Immuno-oncology. As compared to the conventional cancer therapies, CAR T-cell therapy is the single-dose solution for the treatment of various cancers, significantly for some lethal forms of hematological malignancies.
CAR T-cell therapy mainly involves the use of engineered T-cells, the process starts with the extraction of T-cells through leukapheresis, either from the patient (autologous) or a healthy donor (allogeneic). After the expression of a synthetic receptor (Chimeric Antigen Receptor) in the lab, the altered T-cells are expanded to the right dose and administered into the patient body. where they target and attach to a specific antigen on the tumor surface, to kill the cancerous cells by igniting the apoptosis.
The global CAR T-cell therapy market was valued at $734 million in 2019 and is estimated to reach $4,078 million by 2027, registering a CAGR of 23.91% from 2020 to 2027.
Factors that drive the market growth involve, (1) Increased in funding for R&D activities pertaining to cell and gene therapy. By H1 2020 cell and gene therapy companies set new records in the fundraising despite the pandemic crisis. For Instance, by June 2020 totaled $1,452 Million raised in Five IPOs including, Legend Biotech ($487M), Passage Bio ($284M), Akouos ($244M), Generation Bio ($230M), and Beam Therapeutics ($207M), which is 2.5 times the total IPO of 2019.
Moreover, in 2019 cell therapy companies specifically have raised $560 million of venture capital, including Century Therapeutics ($250M), Achilles Therapeutics Ltd. ($121M in series B), NKarta Therapeutics Inc. ($114M), and Tmunity Therapeutics ($75M in Series B).
(2) Increased in No. of Approved Products, By July 2020, there are a total of 03 approved CAR T-cell therapy products, including KYMRIAH®, YESCARTA®, and the most recently approved TECARTUS™ (formerly KTE-X19). Furthermore, two CAR T-cell therapies BB2121, and JCAR017 are expected to get the market approval by the end of 2020 or in early 2021.
Other factors that boost the market growth involves; (3) increase in government support, (4) ethical acceptance of Cell and Gene therapy for cancer treatment, (5) rise in the prevalence of cancer, and (6) an increase in awareness regarding the CAR T-cell therapy.
However, high costs associated with the treatment (KYMRIAH® cost around $475,000, and YESCARTA® costs $373,000 per infusion), long production hours, obstacles in treating solid tumors, and unwanted immune responses & potential side effects might hamper the market growth.
The report also presents a detailed quantitative analysis of the current market trends and future estimations from 2020 to 2027.
The forecasts cover 2 Approach Types, 5 Antigen Types, 5 Application Types, 4 Regions, and 14 Countries.
The report comes with an associated file covering quantitative data from all numeric forecasts presented in the report, as well as with a Clinical Trials Data File.
Key Findings:
The report has the following key findings:
Topics Covered:
The report covers the following topics:
Forecast Segmentation:
Market forecasts are provided for each of the following sub-markets and their categories:
1- By Approach Type
2- By Antigen Type
3- By Application
4- By Region
CHAPTER 1: INTRODUCTION
1.1 REPORT DESCRIPTION 17
1.2 TOPICS COVERED 19
1.3 KEY MARKET SEGMENTS 20
1.4 KEY BENEFITS 21
1.5 RESEARCH METHODOLOGY 21
1.6 TARGET AUDIENCE 22
1.7 COMPANIES MENTIONED 23
CHAPTER 2: EXECUTIVE SUMMARY
2.1 EXECUTIVE SUMMARY 26
2.2 CXO PROSPECTIVE 29
CHAPTER 3: MARKET OVERVIEW
3.1 MARKET DEFINITION AND SCOPE 30
3.2 KEY FINDINGS 31
3.3 TOP INVESTMENT POCKETS 32
3.4 TOP WINNING STRATEGIES 33
3.4.1. Top winning strategies, by year, 2017-2019* 34
3.4.2. Top winning strategies, by development, 2017-2019*(%) 34
3.4.3. Top winning strategies, by company, 2017-2019* 35
3.5 TOP PLAYER POSITIONING, BY PIPELINE VOLUME, 2019 38
3.6 PORTERS FIVE FORCES ANALYSIS 39
3.7 COVID19 IMPACT ON CELL AND GENE THERAPY (CGT) INDUSTRY 41
3.8 MARKET DYNAMICS 46
3.8.1 Drivers 46
3.8.1.1 Increase in funding for R&D activities of CAR T-cell therapy 46
3.8.1.2 The rise in the prevalence of cancer 47
3.8.1.3 Increase in awareness regarding CAR T-cell therapy 472
3.8.2 Restrains 48
3.8.2.1 The high cost of CAR T-cell therapy treatment 48
3.8.2.2 Unwanted immune responses and side effects 48
3.8.2.3 Long production time 48
3.8.2.4 Obstacles in treating solid tumors 49
3.8.3 Opportunities 49
3.8.3.1 Untapped potential for emerging markets 49
CHAPTER 4: CAR T-CELL THERAPY, A BRIEF INTRODUCTION
4.1 OVERVIEW 50
4.2 SIXTY YEARS HISTORY OF CAR T-CELL THERAPY 51
4.3 CAR T-CELL STRUCTURE AND GENERATIONS 53
4.4 CAR T-CELL MANUFACTURING PROCESSES 56
4.5 PRICING AND PAYMENT MODELS FOR CAR T-CELL THERAPIES 59
CHAPTER 5: CAR T-CELL THERAPY MARKET, BY APPROACH TYPE
5.1 OVERVIEW 61
5.1.1 Market size and forecast 62
5.2 AUTOLOGOUS 63
5.2.1 Key market trends 63
5.2.2 Key growth factors and opportunities 64
5.2.3 Market size and forecast 64
5.2.4 Market size and forecast by country 65
5.3 ALLOGENEIC 66
5.3.1 Key market trends 67
5.3.2 Key growth factors and opportunities 68
5.3.3 Market size and forecast 68
5.3.4 Market size and forecast by country 69
CHAPTER 6: CAR T-CELL THERAPY MARKET, BY ANTIGEN TYPE
6.1 OVERVIEW 70
6.1.1 Market size and forecast 71
6.2 CD19 72
6.2.1 Market size and forecast 73
6.2.2 Market size and forecast by country 743
6.3 CD20 75
6.3.1 Market size and forecast 76
6.3.2 Market size and forecast by country 77
6.4 BCMA 78
6.4.1 Market size and forecast 79
6.4.2 Market size and forecast by country 80
6.5 MSLN 81
6.5.1 Market size and forecast 82
6.5.2 Market size and forecast by country 83
6.6 OTHERS 84
6.6.1 Market size and forecast 85
6.6.2 Market size and forecast by country 86
CHAPTER 7: CAR T-CELL THERAPY MARKET, BY APPLICATION
7.1 OVERVIEW 87
7.1.1 Market size and forecast 88
7.2 ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 89
7.2.1 Market size and forecast 90
7.2.2 Market size and forecast by country 91
7.3 DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) 92
7.3.1 Market size and forecast 93
7.3.2 Market size and forecast by country 94
7.4 MULTIPLE MYELOMA (MM) 95
7.4.1 Market size and forecast 96
7.4.2 Market size and forecast by country 97
7.5 ACUTE MYELOID LEUKEMIA (AML) 98
7.5.1 Market size and forecast 99
7.5.2 Market size and forecast by country 100
7.6 OTHERS 101
7.6.1 Market size and forecast 102
7.6.2 Market size and forecast by country 103
CHAPTER 8: CAR T-CELL THERAPY MARKET, BY REGION
8.1 OVERVIEW 104
8.1.1 Market size and forecast 104
8.2 NORTH AMERICA 105
8.2.1 Key market trends 105
8.2.2 Key growth factors and opportunities 1054
8.2.3 Market size and forecast, by country 106
8.2.4 Market size and forecast, by approach type 106
8.2.5 Market size and forecast, by antigen type 107
8.2.6 Market size and forecast, by application 107
8.2.6.1 U.S. market size and forecast, by approach type 108
8.2.6.2 U.S. market size and forecast, by antigen type 108
8.2.6.3 U.S. market size and forecast, by application 109
8.2.6.4 Canada market size and forecast, by approach type 110
8.2.6.5 Canada market size and forecast, by antigen type 110
8.2.6.6 Canada market size and forecast, by application 111
8.2.6.7 Mexico market size and forecast, by approach type 112
8.2.6.8 Mexico market size and forecast, by antigen type 112
8.2.6.9 Mexico market size and forecast, by application 113
8.3 EUROPE 114
8.4.1 Key market trends 114
8.4.2 Key growth factors and opportunities 114
8.4.3 Market size and forecast, by country 115
8.4.4 Market size and forecast, by approach type 115
8.4.5 Market size and forecast, by antigen type 116
8.4.6 Market size and forecast, by application 116
8.3.6.1 UK market size and forecast, by approach type 117
8.3.6.2 UK market size and forecast, by antigen type 117
8.3.6.3 UK market size and forecast, by application 118
8.3.6.4 Germany market size and forecast, by approach type 119
8.3.6.5 Germany market size and forecast, by antigen type 119
8.3.6.6 Germany market size and forecast, by application 120
8.3.6.7 France market size and forecast, by approach type 121
8.3.6.8 France market size and forecast, by antigen type 121
8.3.6.9 France market size and forecast, by application 122
8.3.6.10 Spain market size and forecast, by approach type 123
8.3.6.11 Spain market size and forecast, by antigen type 123
8.3.6.12 Spain market size and forecast, by application 124
8.3.6.13 Italy market size and forecast, by approach type 125
8.3.6.14 Italy market size and forecast, by antigen type 125
8.3.6.15 Italy market size and forecast, by application 126
8.3.6.16 Rest of Europe market size and forecast, by approach type 127
8.3.6.17 Rest of Europe market size and forecast, by antigen type 127
8.3.6.18 Rest of Europe market size and forecast, by application 128
8.4 ASIA-PACIFIC 129
8.4.1 Key market trends 129
8.4.2 Key growth factors and opportunities 129
8.4.3 Market size and forecast, by country 130
8.4.4 Market size and forecast, by approach type 1305
8.4.5 Market size and forecast, by antigen type 131
8.4.6 Market size and forecast, by application 131
8.4.6.1 China market size and forecast, by approach type 132
8.4.6.2 China market size and forecast, by antigen type 132
8.4.6.3 China market size and forecast, by application 133
8.4.6.4 Japan market size and forecast, by approach type 134
8.4.6.5 Japan market size and forecast by antigen type 134
8.4.6.6 Japan market size and forecast, by application 135
8.4.6.7 India market size and forecast, by approach type 136
8.4.6.8 India market size and forecast, by antigen type 136
8.4.6.9 India market size and forecast, by application 137
8.4.6.10 South Korea market size and forecast, by approach type 138
8.4.6.11 South Korea market size and forecast, by antigen type 138
8.4.6.12 South Korea market size and forecast, by application 139
8.4.6.13 Rest of Asia-Pacific market size and forecast, by approach type 140
8.4.6.14 Rest of Asia-Pacific market size and forecast, by antigen type 140
8.4.6.15 Rest of Asia-Pacific market size and forecast, by application 141
8.5 LAMEA 142
8.5.1 Key market trends 142
8.5.2 Key growth factors and opportunities 142
8.5.3 Market size and forecast, by country 143
8.5.4 Market size and forecast, by approach type 143
8.5.5 Market size and forecast, by antigen type 144
8.5.6 Market size and forecast, by application 144
8.5.6.1 Brazil market size and forecast by approach type 145
8.5.6.2 Brazil market size and forecast, by antigen type 145
8.5.6.3 Brazil market size and forecast, by application 146
8.5.6.4 South Africa market size and forecast, by approach type 147
8.5.6.5 South Africa market size and forecast, by antigen type 147
8.5.6.6 South Africa market size and forecast, by application 148
8.5.6.7 Rest of LAMEA market size and forecast by approach type 149
8.5.6.8 Rest of LAMEA market size and forecast, by antigen type 149
8.5.6.9 Rest of LAMEA market size and forecast, by application 150
CHAPTER 9: CLINICAL TRIALS ANALYSIS & PRODUCT PROFILES
9.1 OVERVIEW 151
9.1.1 No. of Clinical Trials from 1997 to 2019 151
9.1.2 Clinical Trials from 1997 to 2019: Based on Approach Type 152
9.1.3 Clinical Trials from 1997 to 2019: Based on Antigen Type 153
9.1.4 Clinical Trials from 1997 to 2019: Based on Application 154
9.1.5 Clinical Trials from 1997 to 2019: Based on Region 1556
9.2 EXPECTED APPROVALS 156
9.3 APPROVED PRODUCTS PROFILES 157
9.3.1 KYMRIAH® 157
9.3.2 YESCARTA® 159
9.3.3 TECARTUS™ 161
CHAPTER 10: COMPANY PROFILES
10.1 Abbvie Inc. 162
10.2 Adaptimmune Therapeutics Plc 164
10.3 Allogene Therapeutics, Inc. 166
10.4 Amgen, Inc 168
10.5 Anixa Biosciences, Inc. 170
10.6 Arcellx, Inc. 172
10.7 Atara Biotherapeutics, Inc. 173
10.8 Autolus Therapeutics Plc. 175
10.9 Beam Therapeutics, Inc. 177
10.10 Bellicum Pharmaceuticals, Inc. 179
10.11 BioNtech SE 181
10.12 Bluebird Bio, Inc. 183
10.13 Carsgen Therapeutics, Ltd 185
10.14 Cartesian Therapeutics, Inc. 187
10.15 Cartherics Pty Ltd. 188
10.16 Celgene Corporation 189
10.17 Cellectis SA 191
10.18 Cellular Biomedicine Group, Inc. 193
10.19 Celularity, Inc. 195
10.20 Celyad SA 196
10.21 CRISPR Therapeutics AG 198
10.22 Eureka Therapeutics, Inc. 200
10.23 Fate Therapeutics, Inc. 201
10.24 Fortress Biotech, Inc 203
10.25 Gilead Sciences, Inc. 205
10.26 Gracell Biotechnology Ltd 207
10.27 icell Gene Therapeutics 208
10.28 Johnson & Johnson 209
10.29 Juventas Cell Therapy Ltd. 211
10.30 Kuur Therapeutics 212
10.31 Legend Biotech Corp. 213
10.32 Leucid Bio Ltd. 214
10.33 Minerva Biotechnologies Corp. 2157
10.34 Molecular Medicine SPA (Molmed) 216
10.35 Nanjing Bioheng Biotech Co., Ltd. 218
10.36 Noile-Immune Biotech Inc. 219
10.37 Novartis AG 220
10.38 Oxford Biomedica PLC 222
10.39 Persongen Biotherapeutics (Suzhou) Co., Ltd. 224
10.40 Poseida Therapeutics, Inc. 226
10.41 Precigen, Inc. 227
10.42 Precision Biosciences, Inc. 229
10.43 Sorrento Therapeutics, Inc. 231
10.44 Takara Bio Inc. 233
10.45 Takeda Pharmaceutical Company Ltd. 235
10.46 TC Biopharm Ltd. 237
10.47 Tessa Therapeutics Pte Ltd. 238
10.48 Tmunity Therapeutics, Inc. 239
10.49 Unum Therapeutics Inc. 240
10.50 Xyphos Inc. 242
10.51 Ziopharm Oncology, Inc. 243
CHAPTER 11: CONCLUSION & STRATEGIC RECOMMENDATIONS
11.1 STRATEGIC RECOMMENDATIONS 245
11.2 CONCLUSION 247
| Price : US$ 3500 | Date : Nov 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 80 |
| Price : US$ 3500 | Date : Nov 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 142 |
| Price : US$ 3500 | Date : Nov 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 119 |
| Price : US$ 3500 | Date : Nov 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 139 |
| Price : US$ 3500 | Date : Nov 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 116 |
We will be happy to help you find what you need. Please call us or write to us:
Want us to send you latest updates of the current trends, insights, and more, signup to our newsletter (for alerts, special offers, and discounts).
This website is secured Origin CA certificate on the server, Comodo, Firewall and Verified Sitelock Malware Protection
Request Sample 
Request Discount 
Inquire Before Buy
